AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaTransplantation, HomologousMelphalanTransplantation ConditioningCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeRemission InductionStem CellsSalvage TherapyDisease-Free SurvivalHodgkin DiseaseMyeloablative AgonistsEtoposideRecurrenceLymphoma, Non-HodgkinBone Marrow TransplantationHematopoietic Stem Cell MobilizationGraft vs Host DiseaseCytarabineCyclophosphamideCarmustineSurvival RateVincristineBone Marrow PurgingThiotepaHematologic NeoplasmsRetrospective StudiesGraft SurvivalWhole-Body IrradiationHematopoietic Stem CellsSurvival AnalysisLymphoma, Mantle-CellAmyloidosisBusulfanBoronic AcidsDexamethasonePyrazinesAntigens, CD34Kidney TransplantationLymphoma, T-Cell, PeripheralPrognosisAntibodies, Monoclonal, Murine-DerivedFollow-Up StudiesLymphoma, FollicularAutograftsTime FactorsLiver TransplantationDoxorubicinAntineoplastic Agents, AlkylatingThalidomideLeukapheresisTissue DonorsGranulocyte Colony-Stimulating FactorMesenchymal Stem Cell TransplantationPrednisoneIfosfamideTransplantation ChimeraLymphomaPodophyllotoxinImmunosuppressive AgentsInduction ChemotherapyCord Blood Stem Cell TransplantationNeoplasm, ResidualLymphoma, Large B-Cell, DiffuseCell TransplantationMaintenance ChemotherapyLeukemia, Myeloid, AcuteAntineoplastic AgentsEmbryonic Stem CellsMyelodysplastic SyndromesEnteropathy-Associated T-Cell LymphomaHistocompatibility TestingLymphoma, B-CellHeart TransplantationBlood Component RemovalGraft RejectionLeukemia, Plasma CellIdarubicinInfusions, SpinalT-LymphocytesAdult Stem CellsMitoxantroneAntibodies, MonoclonalProspective StudiesNeoplasms, Second PrimaryCell DifferentiationLung TransplantationHistocompatibilityBone MarrowHematopoiesisCells, CulturedFatal OutcomeLeukemia, MyeloidFeasibility StudiesLeukemia
Multiple myelomaHSCTHigh-doseMarrowDonorDiffuse large B-UmbilicalMobilizationProgenitor cell transplantationRecipients2022ASCTLymphomasMalignanciesKidney transplantationPatient's own cellsEngraftmentOutcomesMorbidity and mortaAcute MyeloidPost-Transplant ComplicationsCD34Allogeneic transplantsNewly diagnosedMalignantTherapySurvivalHematopoietic Cell TransplantCyclophosphamideDonorsPlatelets2021ComplicationsClinicalAllogenicHuman leucocyPatientMelphalanRefractory2016HematologyTherCancersLymphoproliferativeNeutrophil
Multiple myeloma15
HSCT20
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • In this report, we summarize the case of a patient with MM status post autologous HSCT and chronic kidney disease who experienced worsening hypertension along with a substantial increase in proteinuria shortly after the initiation of carfilzomib for the treatment of refractory disease. (biomedcentral.com)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • The successful application of HSCT for diseases such as leukemia, lymphoma, myeloma, and inherited blood disorders underscored its broad applicability in clinical practice (Snowden et al. (revistadehematologia.org.mx)
  • The patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT) from human leukocyte antigen (HLA) matched related donor. (bvsalud.org)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (yashfiin.com)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (yashfiin.com)
  • Hematopoietic stem cell transplant (HSCT) has become increasingly used to cure beta thalassemia, and provides the potential to cure ␣ 0 thalassemia. (archive.org)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
High-dose17
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows (if the patient is considered eligible for HDCT and ASCT). (wikipedia.org)
  • Autologous transplants allow the use of high-dose chemotherapy, which provides some patients with a better chance of cure or long-term control of their disease. (leukaemia.org.au)
  • In the week leading up to your transplant you will be given a few days of very high-dose chemotherapy, and sometimes radiotherapy , to destroy your underlying disease. (leukaemia.org.au)
  • These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
  • Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. (bu.edu)
  • Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. (bu.edu)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • For autologous transplantation, the patient receives his or her own bone marrow or stem cells that were collected and frozen before admission for high-dose chemotherapy or radiation. (ucsfhealth.org)
  • We evaluated hematopoietic stem cells according to CD34 expression and aldehyde dehydrogenase (ALDH) activity in peripheral blood and apheresis product samples from patients after mobilization with granulocyte-colony-stimulating factor (G-CSF) alone or G-CSF after high-dose cyclophosphamide (4 g/m(2) once daily, intravenously on day 1). (ogu.edu.tr)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • We extract blood cells, treat the cancer with high-dose chemotherapy , then place the cells back into the patient. (mdanderson.org)
Marrow71
Donor18
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
  • In autologous stem cell transplants, the patient is their own stem cell donor. (leukaemia.org.au)
  • After a 2-year period of regular peritoneal dialysis, she was found to be eligible for a kidney transplant from a deceased donor. (bvsalud.org)
  • Most patients (65%) were transplanted from 10/10-HLA or 9/10-HLA matched unrelated donor, seven patients (14%) received stem cells from matched related donor and ten patients (20%) from haploidentical donor. (bvsalud.org)
  • Lacking an HLA matched sibling, he received a 5/6 HLA matched unrelated donor UCB unit delivering 11.8 ϫ 10 7 nucleated cells/kg. (archive.org)
  • Initial chimerism (STRs) showed approximately 63% donor derived cells, since increasing with 100% T-cell engraftment. (archive.org)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • This allows us to collect more cells in a short period, decrease patient/donor downtime and freeze the cells for future use. (mdanderson.org)
  • For many patients who don't have a well-matched, healthy donor, a cord blood transplant is a viable option. (mdanderson.org)
  • If the donor cells aren't a close enough match, the patient's body may recognize the donor cells as foreign and reject them. (mdanderson.org)
  • Or, the cells from the donor may recognize the new body as foreign and attack. (mdanderson.org)
  • Allogeneic stem transplant is another form wherein the stem cells are donated to the person from a genetically matched stem cell donor. (advancells.com)
  • If a donor's HLAs match well with a person who needs a transplant, the donor must give a new blood sample to confirm the match. (medlineplus.gov)
  • Donor stem cells can be collected in two ways. (medlineplus.gov)
  • Most donor stem cells are collected through a process called leukapheresis. (medlineplus.gov)
  • During the collection, blood is removed from the donor through a line in a vein (IV). (medlineplus.gov)
  • The red blood cells are returned to the donor through an IV in the other arm. (medlineplus.gov)
Diffuse large B-3
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). (elsevierpure.com)
Umbilical8
  • 1987). Umbilical cord blood was recognized as an alternative source of hematopoietic stem cells (Gluckman et al. (revistadehematologia.org.mx)
  • months of age and one a 5/6 HLA matched sibling umbilical cord blood transplant (UCBT). (archive.org)
  • Umbilical cord hematopoietic stem cell transplantation has been restricted mainly to children because there are too few stem cells in umbilical cord blood for an adult. (msdmanuals.com)
  • The technique for umbilical cord hematopoietic stem cell transplantation is still in its infancy, but it is gaining interest. (msdmanuals.com)
  • For umbilical cord blood harvest, the cord is clamped after delivery of the baby, and blood is drawn from the cord with a needle and collected in a sterile bag. (msdmanuals.com)
  • The cells for a cord blood transplant come from an umbilical cord collected at birth by the MD Anderson Cord Blood Bank . (mdanderson.org)
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
Mobilization8
  • 1989). Hematopoietic stem cells could be harvested easier from peripheral blood after mobilization with G-CSF (Sheridan et al. (revistadehematologia.org.mx)
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. (elsevierpure.com)
  • According to our data, numbers of SSClo ALDH(br) cells are in very good agreement with numbers of SSClo CD45(dim) CD34(hi) cells and can be a predictor of stem cell mobilization. (ogu.edu.tr)
  • This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)
  • Quantitating the CD34+ cell population can also be useful during mobilization as well as for determining the optimal timing of apheresis sessions to make sure that enough CD34+ cells have been harvested. (bdbiosciences.com)
Progenitor cell transplantation2
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
Recipients4
  • Gassas A , Grant R , Richardson S , Dupuis LL , Doyle J , Allen U , Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. (cdc.gov)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Presence of KIR2DL2/S2, KIR2DL5, and KIR3DL1 Molecules in Liver Transplant Recipients with Alcoholic Cirrhosis Could Be Implicated in Death by Graft Failure. (cdc.gov)
20221
ASCT4
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • This trial confirmed the results of other trials that demonstrated a substantial incidence of symptomatic hypotension in MM patients in the peri-transplant period following ASCT. (astct.org)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
Lymphomas7
  • Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. (biomedcentral.com)
  • The International PTCL project that collected 1314 cases of T/NK-cell lymphomas from 22 institutions worldwide revealed that the most common subtypes worldwide are the nodal T cell lymphomas [ 2 ]. (biomedcentral.com)
  • In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. (biomedcentral.com)
  • however, outcomes are poor when PTCL is treated according to strategies established for aggressive B cell lymphomas [ 3 ]. (biomedcentral.com)
  • Pretargeted Radioimmunotherapy for B-cell Lymphomas. (fredhutch.org)
  • Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. (astct.org)
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
Malignancies4
  • In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. (wikipedia.org)
  • We assessed late mortality in 854 individuals who had survived 2 or more years after autologous hematopoietic cell transplantation (HCT) for hematologic malignancies. (qxmd.com)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. (fredhutch.org)
Kidney transplantation3
Patient's own cells1
  • An autologous stem cell transplant uses the patient's own cells for treatment. (mdanderson.org)
Engraftment3
  • Cell therapy is a potential new treatment for post MI patients, but the main challenges are : the necessity to preserve immune competency and to gain adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • Repair of scar tissue constitutes a challenge for cardiac stem cell therapy due to lack of adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • We also investigated the relationship between the number of SSClo CD45(dim) CD34(hi) cells, SSClo ALDH(br) cells and engraftment. (ogu.edu.tr)
Outcomes7
  • Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. (stembook.org)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
  • Cell therapy is currently emerging as a potential new treatment for post MI patients with the assumption that recolonization of the areas of scarred myocardium with exogenously supplied surrogates or precursors of cardiomyocytes can restore function and ultimately affect clinical outcomes. (escardio.org)
  • The research team is working to reduce treatment toxicity and improve patient outcomes using leading-edge research to advance hematopoietic stem cell transplant methods. (lovesorghum.com)
  • Physicians and scientists work side by side to set standards for stem cell transplantation and improve long-term outcomes for both pediatric and adult patients. (lovesorghum.com)
  • The team has access to a large transplant patient population, rich historical data and a clinical department with a reputation for outstanding transplant outcomes for the past 12 consecutirve years. (lovesorghum.com)
  • In this month's Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SCT, impact of MRD status before alloHCT on outcomes in secondary AML, low-dose post- transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of GVHD in MUD SCT and more. (astct.org)
Morbidity and morta2
  • 1980). As with many countries embarking on this procedure, there were challenges related to transplant-related morbidity and mortality. (revistadehematologia.org.mx)
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
Acute Myeloid1
Post-Transplant Complications1
  • There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. (elsevierpure.com)
CD3411
  • There was no difference in the number of CD34 + cells among PBSC between the non-rituximab and the rituximab groups. (elsevierpure.com)
  • Numbers of SSClo CD45(dim) CD34(hi) cells and SSClo ALDH(br) cells were highly correlated in both peripheral blood and apheresis products (P (ogu.edu.tr)
  • We could not find a relationship between the transplanted SSClo CD45(dim) CD34(hi) cell dose or SSClo ALDH(br) cell dose and platelet or neutrophil recovery. (ogu.edu.tr)
  • The optimal thresholds for SSClo CD45(dim) CD34(hi) cells were 5.40 x 106/kg for neutrophil recovery and 7.22 x 106/kg for platelet recovery. (ogu.edu.tr)
  • 2 Evaluation of harvest adequacy requires the use of reliable progenitor cell assays and this is usually achieved by CD34 cell counting using flow cytometry. (bdbiosciences.com)
  • 4 CD34 expression is historically related to hematopoietic cells and it is considered as the marker of HSCs. (bdbiosciences.com)
  • An accurate measurement of CD34 is critical for dose requirement protocols in stem cell transplantation. (bdbiosciences.com)
  • 6 Fluorochrome-conjugated monoclonal antibodies directed against CD34 molecule can be used to identify CD34+ cells by flow cytometry. (bdbiosciences.com)
  • The BD ® Stem Cell Enumeration (SCE) Kit provides simultaneous enumeration of viable dual-positive CD45+/CD34+ hematopoietic stem cell populations in CD34+ absolute counts (cells/µL) as well as the percentage of the total viable leucocyte count that is CD34+ (%CD34). (bdbiosciences.com)
  • Single-platform flow cytometric absolute cell counting protocols have been shown to provide increased robustness of CD34 enumeration by limiting potential sources of imprecision. (bdbiosciences.com)
  • Endothelial progenitor cell marker CD34 + cell transplantation has been shown to promote angiogenesis in ischemic limbs. (clinicaltdd.com)
Allogeneic transplants2
Newly diagnosed4
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • A total of 179 transplant-eligible patients with newly diagnosed MM treated at a single academic center were included. (biomedcentral.com)
  • C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. (inhibitorkit.com)
Malignant1
  • The malignant cells of ALL are lymphoid precursor cells (ie, lymphoblasts) that are arrested in an early stage of development. (medscape.com)
Therapy16
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • As such, stem cell therapy cannot be regarded as a valid therapeutic option for patients with cardiovascular disease in the present era of evidenced-based medicine, yet it holds great hope for the future. (escardio.org)
  • Preclinical and some small-scaled clinical trials have suggested feasibility and safety of cardiac stem cell therapy. (escardio.org)
  • The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. (elsevierpure.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). (ashpublications.org)
  • Hematology/ Oncology and Stem Cell Therapy. (elsevierpure.com)
  • 0.5 x 109 cells/kg and being transplanted in CR1 versus CR/PR from second-line therapy were identified as independent predictors for OS and PFS. (astct.org)
  • In a combined analysis of categorical groups, the patients in the high A- ALC group transplanted in CR1 had the best prognosis for OS and PFS and patients in the low A- ALC group transplanted in CR/PR after second-line therapy had the worse prognosis for OS and PFS. (astct.org)
  • Collectively, although scientists are increasingly aware of mitochondria's dynamic and transferable capabilities of mitochondria, the unclear mechanism and effectiveness of mitochondrial transfer/transplantation therapy limit its widespread application in diseases. (biomedcentral.com)
  • Stem cell treatment has been widely accepted as the future of medical technology, therapy and any kind of treatment for health hazards. (advancells.com)
  • It is important for the patient to answer the basic questions of whether I am a candidate for stem cell therapy, (2) What kind of cells do I need? (advancells.com)
  • At present, only guidelines are doing the rounds, which have resulted in the escalation of many clinics, hospitals, and nursing homes, claiming successful treatment by stem cell therapy. (advancells.com)
Survival8
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • 1 Significant advances have been made by combining novel agents with autologous peripheral blood stem cell transplantation which allows for long-term disease-free survival in the majority of transplant-eligible patients. (haematologica.org)
  • It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. (uchicago.edu)
  • Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. (uchicago.edu)
  • Therefore, this prospective study aimed to investigate the influence of transplanted cells with cluster of differentiation (CD)184+ expression, CD26+ lymphocytes and monocytes, and reconstitution of CD3+ lymphocytes on overall survival (OS) and progression-free survival (PFS) after auto-SCT in MM. Forty-eight patients with MM underwent auto-SCT at our center from 2011 to 2013. (bvsalud.org)
  • Post-transplant anti-HLA antibodies are associated with worse graft survival. (optumhealtheducation.com)
  • Intercellular mitochondrial transfer can be regarded as an extension of intracellular mitochondrial movement or intercellular communication, which undoubtedly increases the mtDNA content of the recipient cells and restores the respiration and survival of the recipient cells. (biomedcentral.com)
Hematopoietic Cell Transplant1
  • Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. (stembook.org)
Cyclophosphamide1
Donors4
  • Exclusion of prospective blood donors based on their acknowledged risk behaviors for human immunodeficiency virus (HIV) infection began in 1983 (1). (cdc.gov)
  • In 1985, when tests for HIV antibody became available, screening prospective donors of blood, organs, and other tissues also began (2,3). (cdc.gov)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • Allogeneic hematopoietic stem cell transplantation is limited mainly by lack of histocompatible donors. (msdmanuals.com)
Platelets1
  • During this time you will be more at risk of infections (due to the lack of infection-fighting white blood cells ) and bleeding (due to a lack of platelets ). (leukaemia.org.au)
20211
Complications2
  • Moreover, she underwent effective double transplantations and was eventually found to be cured despite accompanying complications. (bvsalud.org)
  • Two weeks before the current visit, he received a transfusion of 2 units of red blood cells to treat anemia , but complications were documented. (medscape.com)
Clinical12
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • Various cell types have been tested experimentally for cardiac repair so far, but only those of autologous origin have yet undergone clinical testing due to immune competency. (escardio.org)
  • abstract： PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
  • Scientists working in basic, translational, and clinical cancer metabolism research are invited to join the Academy in New York on April 17th to discuss the intersection between cell signaling and metabolism. (nyas.org)
  • In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence. (clinicaltdd.com)
  • In recent years, clinical trials with stem cells have taken the emerging field in many new directions. (biomedcentral.com)
  • The rapid advance of stem cell clinical trials for a broad spectrum of conditions warrants an update of the review by Trounson (2009) [ 1 ]. (biomedcentral.com)
  • There has been a rapid surge in clinical trials involving stem cell therapies over the last two to three years and those trials are establishing the clinical pathways for an emergent new medicine. (biomedcentral.com)
  • Placenta-derived stem cells are being considered for similar uses and are in Phase III clinical trial for critical limb ischemia by Israel's Pluristem Therapeutics. (biomedcentral.com)
  • We have chosen to concentrate on the emerging therapeutics that broadly involves a wide range of cell types in clinical trials registered on the National Institutes of Health's clinical trials web site. (biomedcentral.com)
  • Observing the everyday advancements in stem cell technology from the research and clinical perspective, stem cells do promise a healthy future for the coming generations in India. (advancells.com)
Allogenic1
  • With an allogenic transplant, the donor's genes must at least partly match the recipient's genes. (medlineplus.gov)
Human leucocy1
Patient9
  • These cells are collected in advance (while they are in remission ) and returned to the patient at a later stage. (leukaemia.org.au)
  • Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. (shengsci.com)
  • This procedure starts with the patient receiving intensive chemotherapy with or without total body irradiation in an attempt to kill all cancerous cells. (lovesorghum.com)
  • The patient has low blood counts until the replaced cells replenish the patient's body with healthy cells. (mdanderson.org)
  • An allogeneic stem cell transplant is similar, but we take cells from someone other than the patient. (mdanderson.org)
  • Once the cancer is less active and the patient has been pre-treated with chemotherapy (known as conditioning), he or she receives the donor's healthy stem cells. (mdanderson.org)
  • However, the patients must understand that stem cell transplants turn out to be successful in 50-60 per cent cases and that too just in improving the condition of the patient. (advancells.com)
  • Since the lab processing the cells is of a major importance, it is advisable that the patient should visit the lab where the cells are being processed and the hospital where the procedure is to be performed. (advancells.com)
  • As a result of persistent hypotension, the patient was transfused with 3 units of uncrossmatched, type O red blood cells. (medscape.com)
Melphalan1
  • Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. (bu.edu)
Refractory1
20161
Hematology1
  • 8 The BD ® Stem Cell Enumeration Kit incorporates BD Trucount™ tubes to determine the absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts. (bdbiosciences.com)
Ther2
Cancers4
  • Autologous transplants are used to treat a number of different blood cancers. (leukaemia.org.au)
  • Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B cell cancers. (fredhutch.org)
  • Blood cancers multiply uncontrollably, hindering the growth of these cells. (mdanderson.org)
  • Although this form of transplant offers the best chance of curing a number of blood cancers and other serious diseases, it is much riskier than autologous transplants. (advancells.com)
Lymphoproliferative1
  • Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
Neutrophil1
  • The optimal thresholds for SSClo ALDH(br) cells were 6.53 x 106/kg for neutrophil recovery and 8.72 x 106/kg platelet recovery. (ogu.edu.tr)